Cardiovalve

Cardiovalve is developing cardiovascular replacement devices for minimally invasive surgery. Its flagship system is designed to replace the mitral valve using a transfemoral system. Cardiovalve is designed from the bottom up for transfemoral/transseptal delivery with femoral venous access. This approach offers significant benefits including a short profile for minimal protrusion to the left ventricle, minimizing interference in the cardiac blood flow, and increased safety. The company aims to bring to market a viable, clinically proven transfemoral alternative to open-heart surgery in which mitral regurgitation treatments are easier to perform for physicians, enabling patients to return to a healthy life after a quicker recovery. Cardiovalve received FDA approval for an Early Feasibility Study of its Transcatheter Tricuspid Valve Replacement System for a tricuspid regurgitation indication. The Cardiovalve System has also been granted Breakthrough Device Designation status by the FDA. Cardiovalve is a spin-off of Valtech Cardio, which was acquired by Edwards Lifesciences in 2017.

Cardiovalve has raised $45.48M in total funding across 2 rounds. The company is currently at the Acquired stage. Key investors include Edwards Lifesciences, OXO Ventures, NGN Capital.

Cardiovalve was founded in 2017 by Amir Gross (CEO).

Cardiovalve operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Materials & Substances. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Patients.

Cardiovalve is based in Yehadut Canada St 1, Or Yehuda, Israel, Center District.